Skip to content

A study comparing vilazodone with escitalopram in terms of efficacy , safety and onset of action in patients with depression.

A comparative study of efficacy, safety and onset of action of vilazodone with escitalopram in patients of major depressive disorder at tertiary care hospital.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/017302
Enrollment
92
Registered
2019-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F329- Major depressive disorder, singleepisode, unspecified

Interventions

Intervention1: Tablet Vilazodone OD orally.: Drug will be started at a dose of 10mg,dose will be increased every week by 10mg(max upto 40 mg)if inadequate response is obtained. Control Intervention1:

Sponsors

Dr Ankushe rohini
Lead Sponsor
Dr VSDeshmukh
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients of either sex with age between 18 to 65 years. 2)Newly diagnosed MDD patients meeting DSM- 5 criteria for depression. 3)Patient who give written informed consent.

Exclusion criteria

Exclusion criteria: 1)Pregnant or nursing women. 2)Patients with high risk of suicidal tendency or previous suicide attempt within 6 months. 3)Patients with bipolar disorder, drug abuse or dependency, post traumatic stress disorder, obsessive â?? compulsive disorder. 4)Patients with previous depression resistant to antidepressants and those who had taken treatment with electroconvulsive therapy in previous 3 months or formal psychotherapy within 1 month. 5)Patients on other antidepressants. 6)Patients with neurological disorders (dementia, seizures, stroke), obesity with functional impairment, serious or unstable organic disorder (neoplasia, cardiovascular, pulmonary,uncontrolled type 1 or 2 diabetes). 7)Any other medical disorder which is confounding our inclusion diagnosis. 8)Patients with drug intake for psychosis or anxiety. 9)Any history of allergy to the drugs.

Design outcomes

Primary

MeasureTime frame
Outcome name : 1)Hamilton Depression Rating Scale.(used for sample size calculation. ) 2)Udvalg for Kliniske Undersolgelser(UKU)scale. 3)Blood investigations[CBC, SGOT,SGPT ,serum bilirubin(direct and indirect) serum creatinine & serum urea.]Timepoint: Time point : 12 weeks .

Secondary

MeasureTime frame
Outcome name: 1)Hamilton Anxiety Rating Scale(HAM-A). 2)Montgomery-Asberg Depression Rating Scale(MADRS). 3)Clinical Global Impression Scale(CGI)involving, Clinical Global Impression-Severity(CGI-S) and Clinical Global Impression-Improvement(CGI-I)score.Timepoint: Time point: 12 weeks

Countries

India

Contacts

Public ContactDr Ankushe Rohini

Government Medical College, Latur.

vinod_deshmukh88@yahoo.com09405102432

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026